PHENYLEPHRINE

US Approved OTC

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H13NO2
Molecular Weight	167.205
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC[C@H](O)C1=CC(O)=CC=C1

InChI

InChIKey=SONNWYBIRXJNDC-VIFPVBQESA-N

InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C9H13NO2
Molecular Weight	167.205
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00388
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html

Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities. Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Alpha-1a adrenergic receptor 64 Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00388	Agonist 2637	55.0 nM [EC50]
Alpha-1b adrenergic receptor 42 Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25813897	Agonist 2637	5.9 nM [EC50]
Alpha-1d adrenergic receptor 34 Target ID: CHEMBL326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8831777	Agonist 2637	154.88 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypotension 28 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf	Primary		Approved 8307	VAZCULEP Approved Use VAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Launch Date -5.05007997E11
Eye diseases 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	Diagnostic		Approved 8307	Phenylephrine Hydrochloride Ophthalmic Solution Approved Use Indicated to dilate the pupil Launch Date -9.7839363E11

C_max

Value	Dose	Analyte	Population
2959 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4492 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1354 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
2346 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3900 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
955.8 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.93 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.64 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.89 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33062792	unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33062792	Disc. AE: Ischemic colitis... AEs leading to discontinuation/dose reduction: Ischemic colitis (acute) Sources: https://pubmed.ncbi.nlm.nih.gov/33062792
40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	Disc. AE: Chest pain, Jaw pain... Other AEs: Nervous system disorders, Headache... AEs leading to discontinuation/dose reduction: Chest pain (1 patient) Jaw pain (1 patient) Other AEs: Nervous system disorders (3.6%) Headache (2.7%) Gastrointestinal disorders (8%) Dry mouth (2.7%) Nausea (3.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	Other AEs: Eye pain, Blurred vision... Other AEs: Eye pain Blurred vision Photophobia Allergic conjunctivitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
250 ug single, intravenous Recommended Dose: 250 ug Route: intravenous Route: single Dose: 250 ug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf

AEs

AE	Significance	Dose	Population
Ischemic colitis	acute Disc. AE	10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33062792	unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33062792
Chest pain	1 patient Disc. AE	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Jaw pain	1 patient Disc. AE	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Dry mouth	2.7%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Headache	2.7%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Nausea	3.6%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Nervous system disorders	3.6%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Gastrointestinal disorders	8%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Allergic conjunctivitis		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Blurred vision		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Eye pain		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Photophobia		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
		CYP1A2 671

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 1620	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/16510159/ Page: 10.0	yes

PubMed

Title	Date	PubMed
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors.	2000 Apr	10742289
Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases.	2000 Apr 11	10737771
Alpha(1) adrenergic agonist induction of p21(waf1/cip1) mRNA stability in transfected HepG2 cells correlates with the increased binding of an AU-rich element binding factor.	2000 Apr 21	10766810
Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy.	2000 Aug	10900171
Gene transfer of endothelial nitric oxide isoform decreases rat hindlimb vascular resistance in vivo.	2000 Aug 10	10954898
Roles of tissue transglutaminase in ethanol-induced inhibition of hepatocyte proliferation and alpha 1-adrenergic signal transduction.	2000 Jul 21	10801782
Fine structure and plasticity of barosensitive neurons in the nucleus of solitary tract.	2000 Jul 3	10861511
Presence of NMDA receptor subunits in the male lower urogenital tract.	2000 Jul-Aug	10901443
The influence of indomethacin on the acth secretion induced by central stimulation of adrenergic receptors.	2000 Jun	10898105
Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.	2000 Jun	10888249
The Rho effector, PKN, regulates ANF gene transcription in cardiomyocytes through a serum response element.	2000 Jun	10843871
Central control of cardiac baroreflex responses during peripheral hyperosmolality.	2000 May	10801282
Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes.	2000 May 5	10788492
alpha(1)-Adrenergic stimulation perturbs the left-right asymmetric expression pattern of nodal during rat embryogenesis.	2000 Nov	11029149
Phenylephrine protects neonatal rat cardiomyocytes from hypoxia and serum deprivation-induced apoptosis.	2000 Sep	11042672
Influence of a multideficient diet from northeastern Brazil on resting blood pressure and baroreflex sensitivity in conscious, freely moving rats.	2001 Feb	11175505
Effects of salt intake and angiotensin II on vascular reactivity to endothelin-1.	2001 Feb	11160616
Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system.	2001 Feb	11158043
Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin.	2001 Feb 1	11166966
Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin.	2001 Feb 13	11171796
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.	2001 Feb 16	11179201
Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles.	2001 Feb 7	11161004
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.	2001 Feb 9	11071898
Methylene blue as a successful treatment alternative for pharmacologically induced priapism.	2001 Jan	11173934
Detection and characterization of cholinergic oscillatory control in the forehead microvasculature in response to systemic alpha-agonist infusion in healthy volunteers.	2001 Jan	11162204
Involvement of Ca2+ -activated K+ channels in ginsenosides-induced aortic relaxation in rats.	2001 Jan	11152372
Effects of LY117018 and the estrogen analogue, 17alpha-ethinylestradiol, on vascular reactivity, platelet aggregation, and lipid metabolism in the insulin-resistant JCR:LA-cp male rat: role of nitric oxide.	2001 Jan	11152369
Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats.	2001 Jan	11150923
Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude.	2001 Jan	11133901
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS.	2001 Jan	11124138
Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats.	2001 Jan	11124127
alpha-Adrenoceptor stimulation-mediated negative inotropism and enhanced Na(+)/Ca(2+) exchange in mouse ventricle.	2001 Jan	11123227
Hepatic neovascularization after partial portal vein ligation: novel mechanism of chronic regulation of blood flow.	2001 Jan	11123194
Effect of gamma-melanocyte-stimulating hormones on baroreflex sensitivity and cerebral blood flow autoregulation in rats.	2001 Jan	11121815
Increased alpha(1)- and alpha(2)-adrenoceptor-mediated contractile responses of human skeletal muscle resistance arteries in chronic limb ischemia.	2001 Jan	11121814
Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle.	2001 Jan	11121374
Novel site-specific chemical delivery system as a potential mydriatic agent: formation of phenylephrine in the iris-ciliary body from phenylephrone chemical delivery systems.	2001 Jan	11064374
Dietary restriction in pregnant rats causes gender-related hypertension and vascular dysfunction in offspring.	2001 Jan 1	11136866
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using.	2001 Jan 12	11164378
Catecholamine inotropes as growth factors for Staphylococcus epidermidis and other coagulase-negative staphylococci.	2001 Jan 15	11164302
Relaxation of rat aorta by adenosine in diabetes with and without hypertension: role of endothelium.	2001 Jan 19	11166736
The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo.	2001 Jan 19	11139479
Insulin-induced relaxation of rat mesenteric artery is mediated by Ca(2+)-activated K(+) channels.	2001 Jan 5	11137870
Phosphatidylinositol 4,5-bisphosphate is acting as a signal molecule in alpha(1)-adrenergic pathway via the modulation of acetylcholine-activated K(+) channels in mouse atrial myocytes.	2001 Jan 5	11029461
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.	2001 Mar	11179087
Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel.	2001 Mar	11179073
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases.	2001 Mar	11179059
Endogenous estrogen mediates vascular reactivity and distensibility in pregnant rat mesenteric arteries.	2001 Mar	11179035
Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence.	2001 Mar	11171825
Regulation of slow wave frequency by IP(3)-sensitive calcium release in the murine small intestine.	2001 Mar	11171626

Patents

Sample Use Guides

In Vivo Use Guide

VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. Dilute before administration. Dosing for treatment of hypotension during anesthesia Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as needed, not to exceed 200 mcg. Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min.

Route of Administration: Intravenous

In Vitro Use Guide

The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist

Substance Class	Chemical Created by `admin` on `Fri Dec 16 16:12:53 UTC 2022` Edited by `admin` on `Fri Dec 16 16:12:53 UTC 2022`
Record UNII	1WS297W6MV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PHENYLEPHRINE

Official Name

English

J8.601K

Code

English

M-SYMPATHOL

Common Name

English

M-SYNEPHRINE

Common Name

English

AB-101 (PHENYLEPHRINE)

Code

English

(R)-PHENYLEPHRINE

Common Name

English

(-)-3 HYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZENEMETHANOL

Systematic Name

English

PHENYLEPHRINE, (R)-

Common Name

English

PHENYLEPHRINE MINIMS

Brand Name

English

R(-)-MEZATON

Common Name

English

PHENYLEPHRINE [HSDB]

Common Name

English

(-)-1-(3-HYDROXYPHENYL)-2-METHYLAMINOETHANOL

Systematic Name

English

M-OXEDRINE

Common Name

English

Phenylephrine [WHO-DD]

Common Name

English

PHENYLEPHRINE [VANDF]

Common Name

English

PHENYLEPHRINE [MI]

Common Name

English

META-SYNEPHRINE

Common Name

English

phenylephrine [INN]

Common Name

English

M-SYMPATOL

Common Name

English

PHENYLEPHRINE [EP IMPURITY]

Common Name

English

PHENYLEPHRINE [EP MONOGRAPH]

Common Name

English

METASYNEPHRINE

Common Name

English

(-)-PHENYLEPHRINE

Common Name

English

PHENYLEPHRINE [MART.]

Common Name

English

Classification Tree Code System Code

LIVERTOX

773